Jaslok Hospital Announces Stem Cell Treatment for PD
Also announces launch of a new website and a new drug to
cure the disease
Actress Dimple Kapadia with the neurology team of Jaslok
On World Parkinson's Day, Jaslok Hospital & Research Centre,
Mumbai announced the launch of a revolutionary Mesenchymal stem cell project
along with Reliance Life Sciences to treat Parkinson's Disease (PD). A new drug
delivery system Duodopa to manage PD with Continuous Dopaminergic Stimulation
was also announced.
A website www.parkinsonsgroup.com was also launched for PD
patients and caregivers by actress Dimple Kapadia. Several patients and their
caregivers were also present to narrate their experiences in living with and
dealing with PD.
Said Dr Paresh Doshi, HOD, Department of Stereotactic and Functional Neurosurgery,
Jaslok Hospital, "This path breaking project will be a benchmark in the
field of neurology. We will explore the use of Mesenchymal stem cells for the
cure of the disease. The cells found in the patient's own bone marrow will be
taken to Reliance Life Sciences laboratory, which has one of the highest standards
and technique to process these cells. Here they will be isolated, multiplied
and induced towards neuronal differentiation. At each stage of their maturity,
they will be screened for any damage or abnormality. Once they reach a certain
number they will be shipped back to us, where we will implant them in the patients
using stereotactic techniques. As the cells are from the patient's own bone
marrow there is no potential of rejection and side effects are also negated
as they can multiply only for a limited time."
He added, "The project will be different from others because of the unique
techniques that we will be using on human trials. These techniques are based
on extensive animal experiments which have yielded positive results. Other similar
trials have been unsuccessful due to methodical issues. This project has undergone
the intense scientific and ethics committee review, and will be undertaken with
highest levels of safety."
Said Dr Noshir H Wadia, Director, Department of Neurosciences, Jaslok Hospital
& Research Centre, "With all these path-breaking initiatives, Jaslok
Hospital has now emerged as the final destination for all PD patients."
The new drug called Duodapa for the treatment of motor fluctuations comprises
a concentrated levodopa/carbidopa (drug) gel formulation that is administered
into the small intestine via a tube through an external pump. As the infusion
is continuous, patients carry the pump with them all the time and can avoid
EH News Bureau